Comparison of preference for NovoPen(®) 4 with previous insulin pen treatments after 12 weeks in adult patients with type 1 and type 2 diabetes: a multicenter observational study.

Background: In separate randomized, crossover trials, patients with diabetes reported a preference for durable insulin pen NovoPen(®) 4 compared with NovoPen 3 and OptiClik(®).

Objective: This large post-marketing observational study evaluated treatment satisfaction with NovoPen 4 versus previous treatments, which included NovoPen 3 and other devices, in insulin-treated and insulin-naive patients.

Methods: During regular clinical practice in Canada, Germany, and the Netherlands, health care professionals assigned adult patients with type 1 or type 2 diabetes to treatment with insulin administered via NovoPen 4 after training according to the device's instruction manual.